logo

Why Is Nanocap Immuneering Stock Trading Higher On Friday? - Immuneering ( NASDAQ:IMRX )

  6 days ago   
post image
On Thursday, Immuneering Corporation IMRX released initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer as part of its ongoing Phase 2a trial.
Ticker Sentiment Impact
TOP
Somewhat Bullish
10 %